Search hospitals > Nebraska > Omaha
University of Nebraska Medical Center
Claim this profileOmaha, Nebraska 68105
Global Leader in Lymphoma
Global Leader in Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Parotid Gland Cancer
Conducts research for Relapse
1232 reported clinical trials
94 medical researchers
Summary
University of Nebraska Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Lymphoma, Cancer, Adult T-Cell Leukemia/Lymphoma, Parotid Gland Cancer, Relapse and other specialties. University of Nebraska Medical Center is involved with conducting 1,232 clinical trials across 1,415 conditions. There are 94 research doctors associated with this hospital, such as Jill C. Beck, Minnie Abromowitch, Jonathan Thompson, MD, and Matthew Lunning, DO.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage II
Stage III
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jill C. BeckChildren's Hospital and Medical Center of Omaha5 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
54 reported clinical trials
110 drugs studied
Minnie AbromowitchChildren's Hospital and Medical Center of Omaha8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
41 reported clinical trials
86 drugs studied
Jonathan Thompson, MDMedical College of Wisconsin5 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
23 drugs studied
Matthew Lunning, DOUniversity of Nebraska Medical Center7 years of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
13 reported clinical trials
40 drugs studied
Clinical Trials running at University of Nebraska Medical Center
Lung Cancer
Breast Cancer
Cancer
Lymphoma
Non-Small Cell Lung Cancer
Prostate Cancer
Brain Tumor
Multiple Myeloma
Testicular cancer
Skin Cancer
Serplulimab + Chemotherapy
for Small Cell Lung Cancer
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Recruiting3 awards Phase 32 criteria
MK-2870
for Non-Small Cell Lung Cancer
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
Recruiting2 awards Phase 39 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Nebraska Medical Center?
Where is University of Nebraska Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Nebraska Medical Center accept?
What awards or recognition has University of Nebraska Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.